After decades of limited progress—owing to the difficulty of treating the disease and resultant market risk—glioblastoma ...

Russian scientists have created a microfluidic platform that replicates blood flow in the brain. It is capable of supporting ...

A group led by the Department of Neurosurgery at the Brain Research Institute, Niigata University, has successfully treated a patient with a brainstem glioma harboring a rare IDH2 mutation.

In July 2025, Inovio Pharmaceuticals conducted a Phase 1/2 trial to evaluate safety, immunogenicity and preliminary efficacy of INO-5401 and INO-9012 in combination with cemiplimab (REGN2810), with ...

A group led by the Department of Neurosurgery at the Brain Research Institute, Niigata University, has successfully treated a patient with a brainstem glioma harboring a rare IDH2 mutation. The case ...

A group at Niigata University succeeded in the treatment of a brainstem glioma patient with a rare IDH2 mutation. Brainstem gliomas with H3K27M mutation are usually refractory to temozolomide ...

The addition of temozolomide to radiation therapy prolonged OS for patients with both co-deleted and non-co-deleted grade 2 gliomas, according to study results.These are the first data from a ...

Concomitant radiotherapy plus temozolomide significantly increased progression-free survival versus radiotherapy alone in IDH-wildtype glioblastoma.

Veliparib addition to temozolomide did not significantly extend overall survival in MGMT-hypermethylated glioblastoma patients. The investigational combination was well tolerated, with no significant ...

Both radiation and temozolomide, a generic chemotherapy treatment in pill form, have meaningful single-modality anti-tumor activity against slow-growing, low-grade gliomas.